Safety and appropriate use of salmeterol in the treatment of asthma

Journal of Allergy and Clinical Immunology

Volumn 98, Issue 3, 1996, Pages 475-480

  Welch, Michael J ^b   Szefler, Stanley J ^b   Nelson, Harold S ^b   Apter, Andrea J ^b   Brandon, Milan L ^b   Chervinsky, Paul ^b   Hannaway, Paul J ^b   Hendeles, Leslie ^b   Katz, Roger M ^b   Kemp, James P ^b   Melamed, Julian ^b   Nicklas, Richard A ^b   Rowe, Michael S ^b   Simons, Estelle ^b   Woehler, Thomas R ^b   Ziering, William H ^b  

^a American Academy of Allergy Asthma & Immunology   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CROMOGLYCATE DISODIUM; GLUCOCORTICOID; NEDOCROMIL; PIRBUTEROL; SALBUTAMOL; SALMETEROL; TERBUTALINE; THEOPHYLLINE;

ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG USE; HEADACHE; HUMAN; HYPOKALEMIA; INHALATIONAL DRUG ADMINISTRATION; MORTALITY; ORAL DRUG ADMINISTRATION; PHARMACEUTICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SUSTAINED RELEASE PREPARATION; TACHYCARDIA; TREMOR;

EID: 0029861347     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-6749(96)70078-7     Document Type: Article

References (30)

1. 2-adrenergic agonists in asthma. J Allergy Clin Immunol 1993;91:1234-7.
2. Clark CE, Ferguson AD, Siddorn JA. Respiratory arrests in young asthmatics on salmeterol. Respir Med 1993;87:227-8.
3. "Dear Doctor" communication. Allen and Hanburys, January 16, 1995.
4. Finkelstein FN. Risks of salmeterol? [letter]. N Engl J Med 1994;331:1314.
5. 2-agonist. Ann Pharmacother 1993;27:1478-87.
6. Johnson M, Butchers PR, Coleman RA, Nials AT, Strong P, Summer MJ, et al. The pharmacology of salmeterol. Life Sci 1993;52:2131-43.
7. 2 agonists in the treatment of asthma? Chest 1995;107:1116-24.
8. Mann RD. Results of prescription event monitoring study of salmeterol [letter]. BMJ 1994;309:1018.
9. Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 1993;306:1034-7.
10. Bunney R. Study too small to detect increase in deaths [letter]. BMJ 1993;306:1610.
11. Sears MR, Taylor DR. Increase in deaths during salmeterol treatment unexplained [letter]. BMJ 1993;306:1610-1.
12. Crompton GK. Regular treatment with B agonists remains unevaluated [letter]. BMJ 1993;306:1610.
13. Faurschou P. Chronic dose-ranging studies with salmeterol. Eur Respir Rev 1991;1:282-7.
14. Britton MG, Earnshaw JS, Palmer JBD. A twelve month comparison of salmeterol with salbutamol in asthmatic patients. Eur Respir J 1992;5:1062-7.
15. Lundback B, Rawlinson DW, Palmer JBD. A twelve month comparison of salmeterol and salbutamol as dry powder formulations in asthmatic patients. Thorax 1993;48:148-53.
16. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994;344:219-24.
17. Pearlman DS, Chervinsky P, LaForce C, et al. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N Engl J Med 1992;327:1420-5.
18. D'Alonzo GE, Nathan RA, Henochowicz S, Morris RJ, Ratner P, Rennard SI. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with, asthma. JAMA 1994;271:1412-6.
19. 2-receptor function and inflammatory cells. Allergy 1992;47:477-83.
20. 2U. Palmer JBD. Salmeterol in clinical practice. Eur Respir Rev 1991;1:297-300.
21. Ramage I, Lipworth BJ, Ingram CG, Cree IA, Phillon DP. Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respir Med 1994;88:363-8.
22. 2 adrenoreceptor antagonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med 1992;327:1198-203.
23. 2 agonist salmeterol in mild to moderate asthmatic patients. Thorax 1993;48:121-4.
24. Grove A, Lipworth BJ. Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. Lancet 1995;346:201-6.
25. Ullman A, Hedner J, Svedmyr N. Inhaled salmeterol and salbutamol in asthmatic patients: an evaluation of asthma symptoms and the possible development of tachyphylaxis. Am Rev Respir Dis 1990;142:571-5.
26. Wilkinson JRW, Roberts JA, Bradding P, Holgate ST, Howarth PH. Paradoxical bronchoconstriction in asthmatic patients after salmeterol by metered dose inhaler. BMJ 1992;305:931-2.
27. Ayres JG, Benincasa C. Acute bronchoconstriction following the use of salmeterol xinafoate via the metered-dose inhaler in adult asthmatics [abstract]. Am Rev Respir Dis 1993;147;4(part 2):A61.
28. Global Initiatives for Asthma. Global Strategy for Asthma Management and Prevention NHLBI/WHO Workshop Report. Bethesda: National Institutes of Health; 1995. National Heart, Lung and Blood Institute publication number 95-3659.
29. Kemp JP. Making best use of today's bronchodilators. Presented at "Today's and Tomorrow's Role for Beta-Adrenergic Agents in Managing Asthma" Symposium; November 19-21, 1993;
30. proceedings published J Respir Dis 1994;15(suppl)(4A):S21-27.